AU3809999A - Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes - Google Patents

Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes

Info

Publication number
AU3809999A
AU3809999A AU38099/99A AU3809999A AU3809999A AU 3809999 A AU3809999 A AU 3809999A AU 38099/99 A AU38099/99 A AU 38099/99A AU 3809999 A AU3809999 A AU 3809999A AU 3809999 A AU3809999 A AU 3809999A
Authority
AU
Australia
Prior art keywords
decanones
triazaspiro
novel
high affinity
opioid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38099/99A
Other languages
English (en)
Inventor
Rolf Hohlweg
Christian Thomsen
Brett Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU3809999A publication Critical patent/AU3809999A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU38099/99A 1998-05-18 1999-05-14 Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes Abandoned AU3809999A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DK681/98 1998-05-18
DK68198 1998-05-18
DK71198 1998-05-20
DK711/98 1998-05-20
DK72998 1998-05-26
DKPA199800927 1998-07-10
DKPA 1998-11-12
DKPA199900111 1999-01-29
PCT/DK1999/000266 WO1999059997A1 (fr) 1998-05-18 1999-05-14 Nouvelles 1,3,8-triazaspiro[4.5]decanones possedant une affinite elevee pour les sous-types du recepteur opioide

Publications (1)

Publication Number Publication Date
AU3809999A true AU3809999A (en) 1999-12-06

Family

ID=27512746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38099/99A Abandoned AU3809999A (en) 1998-05-18 1999-05-14 Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes

Country Status (4)

Country Link
EP (1) EP1080091A1 (fr)
JP (1) JP2002515503A (fr)
AU (1) AU3809999A (fr)
WO (1) WO1999059997A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237047T3 (es) * 1998-10-23 2005-07-16 Pfizer Inc. Compuestos de 1,3,8-triazaespiro(4,5)decanona como agonistas del receptor orl1.
AU1382901A (en) * 1999-11-17 2001-05-30 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
AU1623801A (en) 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
DE60022226D1 (de) 1999-12-06 2005-09-29 Euro Celtique Sa Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
JP3989247B2 (ja) 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
EP1244437A4 (fr) 1999-12-06 2005-02-09 Euro Celtique Sa Composes amino tertiaires presentant une affinite pour le recepteur opioide
JP2005231995A (ja) * 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
WO2001060796A1 (fr) * 2000-02-18 2001-08-23 Meiji Seika Kaisha, Ltd. DERIVES DE PHENOXYALKYLAMINE UTILES EN TANT QU'AGONISTES DU RECEPTEUR OPIOIDE $g(d)
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
EP1365756A2 (fr) * 2000-08-15 2003-12-03 Cpd, Llc Methode de traitement du syndrome du diabete de type ii humain
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6969712B2 (en) 2000-11-15 2005-11-29 Banyu Pharmaceutical Co., Ltd. Benzimidazole derivatives
EP1392687B1 (fr) 2001-04-10 2017-02-01 Janssen Pharmaceuticals, Inc. Derives de 1,3,8-triazaspiro[4.5]decan-4-one utiles dans le traitement de troubles induits par le recepteur orl-1
BR0209128A (pt) 2001-04-18 2005-11-01 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
RU2299883C2 (ru) * 2001-04-18 2007-05-27 Эро-Селтик, С.А. Соединения спиропиразола, содержащая их фармацевтическая композиция, способ модуляции опиоидного рецептора и способ лечения с применением таких соединений
CA2443938C (fr) 2001-04-18 2010-06-22 R. Richard Goehring Composes de spiroindene et de spiroindane comme ligands opioides utiles pour le traitement de la douleur
EP1598339B1 (fr) 2001-04-18 2009-06-24 Euro-Celtique S.A. Derivés de la 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one et composés similaires pour l'utilisation comme analogues du nociceptin et ligandes du orl1 pour le traitement de la douleur
SI1385518T1 (sl) 2001-04-18 2009-02-28 Euro Celtique Sa Benzimidazolonske spojine
EP1402899A4 (fr) * 2001-05-08 2009-03-11 Toray Industries Remedes contre la sepsie
WO2002100861A1 (fr) * 2001-06-13 2002-12-19 Akzo Nobel N.V. Derives de 1-(3-phenyloxypropyl)piperidine
DK1491212T3 (da) 2002-03-29 2012-10-29 Mitsubishi Tanabe Pharma Corp Middel til behandling af søvnforstyrrelser
JP2005289816A (ja) 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd ベンズイミダゾール誘導体
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
AU2003268512A1 (en) 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
CA2507159A1 (fr) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Utilisation de loxapine et de amoxapine pour la fabrication d'un analgesique
NZ544282A (en) * 2003-05-23 2009-07-31 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
WO2007085357A1 (fr) 2006-01-30 2007-08-02 Euro-Celtique S.A. Composes cyclo-uree utilises en tant que bloqueurs des canaux calciques
WO2008051902A2 (fr) 2006-10-20 2008-05-02 Cpd, Llc Procédé pour rétablir l'effet de l'incrétine
CN101622254B (zh) 2006-11-28 2013-05-29 詹森药业有限公司 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐
JP5490677B2 (ja) 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体
DK2582701T3 (en) * 2010-06-18 2017-02-06 Altos Therapeutics Llc D2 ANTAGONISTS, SYNTHESIS PROCEDURES AND METHODS OF USE
EP3215154B1 (fr) 2014-11-07 2020-01-29 Regents of the University of Minnesota Sels et compositions utiles pour le traitement de maladie
US10787423B2 (en) * 2015-09-14 2020-09-29 The National Institute For Biotechnolgy In The Negev Ltd. Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633914A (fr) * 1962-06-22
US3238216A (en) * 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
US3629267A (en) * 1968-10-28 1971-12-21 Smith Kline French Lab Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione
JPS491573A (fr) * 1972-04-28 1974-01-08
US3923993A (en) * 1973-06-28 1975-12-02 American Home Prod Process for treating neuroendocrinopathic diseases employing fluspirilene
US3863011A (en) * 1973-06-28 1975-01-28 American Home Prod Process for treating neuroendocrinopathic diseases employing pimozide
US4051248A (en) * 1975-07-14 1977-09-27 E. R. Squibb & Sons, Inc. 1,3,8-triazaspiro(4.5)decan-4-one derivatives
WO1991013622A1 (fr) * 1990-03-16 1991-09-19 Beth Israel Hospital Association Utilisation de spiperone comme agent immunosuppresseur et anti-inflammatoire
JPH08500326A (ja) * 1991-12-27 1996-01-16 ベス イスラエル ホスピタル アソシエイション 免疫抑制剤としてのスピペロンまたはスピペロン誘導体の使用

Also Published As

Publication number Publication date
WO1999059997A1 (fr) 1999-11-25
EP1080091A1 (fr) 2001-03-07
JP2002515503A (ja) 2002-05-28

Similar Documents

Publication Publication Date Title
AU3809999A (en) Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
AU5203999A (en) Beta3-adrenergic receptor agonists
AU5640299A (en) 4-quinolinemethanol derivatives as purine receptor antagonists.(ii)
PL346648A1 (en) 4,4-biarylpiperidine derivatives with opioid receptor activity
AU2957997A (en) 1,2,4-oxadiazoles as adhesion-receptor antagonists
HK1034070A1 (en) High affinity ligands for nociceptin receptor orl-1.
AU3633997A (en) Chemokine receptor antagonists
AU2413401A (en) Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
AU7692896A (en) Quinazolin-2,4-diazirines as NPY receptor antagonist
AU6503499A (en) Synthetic peptides having fgf receptor affinity
SI0856514T1 (en) 8-substituted-1,3,8-triazaspiro(4.5)decan-4-on derivatives
AU4394799A (en) Retinoid-associated receptor regulators
AU5640199A (en) 4-quinolinemethanol derivatives as purine receptor antagonists (i)
AU4729699A (en) Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
EP1196417B8 (fr) 1,2,3,4,5,6-HEXAHYDROAZEPINE 4,5-b]INDOLES CONTENANT DES ARYLSULFONES A LA POSITION 9
AU6343998A (en) Constitutively activated serotonin receptors
ZA99453B (en) Adhesion receptor blocker for ÓV-integrins.
AU1948601A (en) Triazospiro compounds having nociceptin receptor affinity
AU3041700A (en) Imidazo(4,5-c)-pyridine-4-on-derivatives
SG79259A1 (en) Diaza-spiro[3,5]nonane deravatives
AU2095099A (en) Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparationand their use as muscarinic receptor (ant-)agonists
AU1882295A (en) Pyrrolo(2,3-(d))pyrimidine derivatives as antivirals
AU1296899A (en) Phenyl-alkyl-imidazoles as h3 receptor antagonists
AU1542000A (en) Seat track with zero chuck lock
AU2517299A (en) Substituted alpha,beta-anellated butyrolactones

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase